Astronaut and Pioneer Sally Ride Dies of Cancer

Sally Ride, one of the great pioneers of the NASA space program and the first American woman to go into orbit, has died from pancreatic cancer at her San Diego home. She was 61.

Ride first made history on 18 June 1983 at just 32 years old when she rode aboard the Space Shuttle Challenger. In the almost thirty years since her historic launch into space, a full 42 American women have followed in her footsteps.

In 1983 she became an instant hero to girls and women the world over, giving them, in the words of President Obama, "a powerful role model" who "inspired young girls to reach for the stars."

Remarkably, NASA only began allowing women to join the space program in 1978—about fifteen years after the Soviet space program became the first to put a woman into orbit. At that time, Ride was one of the initial six women who joined. Five years later she would find herself on the launch pad at the Kennedy Space Center on the cusp of history, with such feminist notables as Gloria Steinem present for the occasion.

Yet for Ride, that historic launch was not a great moment in feminism; it was another day at the office. Her professionalism and her devotion to science are what have contributed to her reputation while with NASA and they remain what will boost her legacy in the future.

Being an astronaut was only part of who Sally Ride was. She was a physicist and children's books author, she taught physics at the University of California at San Diego, and she ran her own company.

Sources: Various outlets

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap